Please read this disclaimer (“disclaimer”) carefully before using the Information Management Toolbox website (“website”, “service”) operated by The European Joint Programme on Rare Diseases (“us”, ‘we”, “our”).

The information and the resources available on this website were collated and verified to the best of our abilities. However, we make no warranties as to the accuracy of the content and assume no liability or responsibility for any error or omission in the content.

Please contact us in case you are the owner of any resource incorrectly represented or linked on this website and we will have it removed or corrected.

All information posted is merely for educational and informational purposes and it is not intended as a substitute for professional advice. Should you decide to act upon any information on this website, you do so at your own risk.

If you are reproducing, reusing, reprinting or republishing  any content available on this website, please do so in accordance with the original copyright holder license.

We reserve the right to change this policy at any given time, of which you will be promptly updated.

The General Pharmaceutical Framework

The EU Commission is preparing a proposal for new legislation (i.e., The General Pharmaceutical Framework) which will impact multiple aspect of drug development in the EU. Modification of the European Agency (EMA) structure and functioning, Rare Disease and Paediatric drug incentives will be affected. The new legislation is expected for the Q4 of 2023 or Q1 of 2024.